Market closed
Renovaro/$RENB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Renovaro
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
Ticker
$RENB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
25
Website
Renovaro Metrics
BasicAdvanced
$133M
-
-$0.82
0.62
-
Price and volume
Market cap
$133M
Beta
0.62
52-week high
$3.38
52-week low
$0.40
Average daily volume
727K
Financial strength
Current ratio
0.06
Quick ratio
0.015
Long term debt to equity
0.822
Total debt to equity
8.755
Interest coverage (TTM)
-27.05%
Management effectiveness
Return on assets (TTM)
-18.09%
Return on equity (TTM)
-188.47%
Valuation
Price to book
1.65
Price to tangible book (TTM)
-5.23
Price to free cash flow (TTM)
-12.503
Growth
Earnings per share change (TTM)
21.95%
3-year earnings per share growth (CAGR)
2.28%
Renovaro Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Renovaro News
AllArticlesVideos
PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI
Business Wire·2 months ago
Renovaro Issues Shareholder Letter and Provides Corporate Update
GlobeNewsWire·2 months ago
Renovaro Appoints Nathen Fuentes as Chief Financial Officer
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Renovaro stock?
Renovaro (RENB) has a market cap of $133M as of February 26, 2025.
What is the P/E ratio for Renovaro stock?
The price to earnings (P/E) ratio for Renovaro (RENB) stock is 0 as of February 26, 2025.
Does Renovaro stock pay dividends?
No, Renovaro (RENB) stock does not pay dividends to its shareholders as of February 26, 2025.
When is the next Renovaro dividend payment date?
Renovaro (RENB) stock does not pay dividends to its shareholders.
What is the beta indicator for Renovaro?
Renovaro (RENB) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.